AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05761223
Drug: Phase Ia dose-escalation part of FB849 Monotherapy
RxNorm normalized name: MAGNESIUM ALUMINOMETASILICATE TYPE IA
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: At a given level dose once daily
Trial: NCT05761223
Drug: Phase IIb dose-escalation part of FB849 in Combination with Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: At recommended dose for expansion cohort once daily in combination with pembrolizumab
Trial: NCT05761223
Drug: Phase IIb dose-expansion part of FB849 in Combination with Pembrolizumab (Type A cancer)
RxNorm normalized name: typhoid, combinations with paratyphi types
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: At recommended dose for expansion cohort once daily in combination with pembrolizumab
Trial: NCT05761223
Drug: Phase IIb dose-expansion part of FB849 in Combination with Pembrolizumab (Type B cancer)
RxNorm normalized name: typhoid, combinations with paratyphi types
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: At recommended dose for expansion cohort once daily in combination with pembrolizumab
Trial: NCT05761223
Drug: Phase IIb dose-expansion part of FB849 in Combination with Pembrolizumab (Type C cancer)
RxNorm normalized name: typhoid, combinations with paratyphi types
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: At recommended dose for expansion cohort once daily in combination with pembrolizumab
Trial: NCT06711185
Drug: Dapagliflozin 10 mg
RxNorm normalized name: dapagliflozin 10 MG
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients in this group will receive 1 tablet of 10mg dapagliflozin daily for 9 months, starting 7-10 days before chemotherapy treatment.
Trial: NCT06713057
Drug: Vindesine + Cisplatin
RxNorm normalized name: vindesine
DrugBank: Vindesine (DB00309)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV or PO
Trial: NCT06713057
Drug: Paclitaxel + Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV or PO
Trial: NCT06713057
Drug: Paclitaxel + Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV or PO
Trial: NCT06291831
Drug: nirmatrelvir, ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients receiving Nirmatrelvir; Ritonavir (PAXLOVID)
Trial: NCT05515120
Drug: Rivaroxaban 20 MG [Xarelto]
RxNorm normalized name: rivaroxaban 20 MG [Xarelto]
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: It was adopted an equal allocation of patients to each treatment (i.e., 1:1 randomization)
Trial: NCT05515120
Drug: Aspirin 300mg
RxNorm normalized name: ASPIRIN 300MG TAB
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: It was adopted an equal allocation of patients to each treatment (i.e., 1:1 randomization)
Trial: NCT06714084
Drug: Neoadjuvant Chemotherapy (NACT)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two cycles of carbonilumab plus TP regimen neoadjuvant chemotherapy will be implemented to patients with advanced cervical cancer
Trial: NCT04721821
Drug: Tofacitinib
RxNorm normalized name: Tofacitinib
DrugBank: Tofacitinib (DB08895)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients who received Tofacitinib for RA
Trial: NCT05381207
Drug: Montelukast Oral Tablet
RxNorm normalized name: montelukast Oral Tablet
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects in group A (study) will be treated with Fluticasone Furoate nasal: (50 micrograms/spray) 100 micrograms (2 sprays) in each nostril twice daily plus oral montelukast (montelukast 10 mg, once a day) for 3 months. Subjects group B (control) will receive only topical steroids in an identical regimen
Trial: NCT00001023
Drug: Rifabutin
RxNorm normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06711913
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intravenous dexmedetomidine given in form of 100ml infusion over 10 minutes
Trial: NCT05763004
Drug: IOS-1002
RxNorm normalized name: Iosat
DrugBank: Potassium Iodide (DB06715)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: monotherapy
Trial: NCT04971720
Drug: Sacubitril-Valsartan 49 Mg-51 Mg Oral Tablet
RxNorm normalized name: sacubitril-valsartan 49 mg-51 mg oral tablet
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The subject will be randomized, in a double-blind manner to sacubitril/valsartan 49/51 mg once in the morning or once in the evening for a period of 28 days.
Trial: NCT04971720
Drug: Valsartan 80 mg Oral Tablet
RxNorm normalized name: VALSARTAN 80 mg ORAL TABLET
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The subject will be randomized, in a double-blind manner to valsartan 80 mg once in the morning or once in the evening for a period of 28 days.
Trial: NCT06496165
Drug: Remimazolam
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous pump injection. The loading dose will be 0.1mg/kg, the maintenance dose will be 0.1-0.5mg/kg/h, with the target RASS be -2-0
Trial: NCT06496165
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous pump injection. The loading dose will be 0.5mg/kg, the maintenance dose will be 1-4mg/kg/h, with the target RASS be -2-0
Trial: NCT04891354
Drug: Sodium chloride (placebo)
RxNorm normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo (NaCl, commercially available dilution solution for parenteral use, 9 mg/mL)
Trial: NCT04921904
Drug: Abemaciclib
RxNorm normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 150mg dose administered orally twice daily every day
Trial: NCT04921904
Drug: Ramucirumab
RxNorm normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 8mg/kg iv every 2 weeks until evidence of disease
Trial: NCT06172660
Drug: Nirsevimab
RxNorm normalized name: Nirsevimab
DrugBank: Nirsevimab (DB16258)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunoprophylaxis against RSV
Trial: NCT05179525
Drug: Risperidone ISM® 100 mg
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 100 mg of risperidone ISM® administered every 4 weeks
Trial: NCT05179525
Drug: Risperdal 4mg Tablet
RxNorm normalized name: Risperdal 4mg Tablet
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 4 mg oral risperidone once daily for 7 days
Trial: NCT04918511
Drug: OPD5
RxNorm normalized name: Oxycodone/Paracetamol/Dextromethorphan/Pseudoephedrine/Doxylamine
DrugBank: Doxylamine (DB00366)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: OPD5 solution for i.v. infusion
Trial: NCT05085184
Drug: administration of UI018
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test
Trial: NCT05085184
Drug: co-administration of UIC201806 and UIC201602
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reference
Trial: NCT06475599
Drug: Anlotinib hydrochloride capsule + TQB2450 injection
RxNorm normalized name: terbinafine
DrugBank: Anlotinib (DB11885)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anlotinib hydrochloride capsule is a multi-target tyrosine kinase inhibitor, which targets VEGFR (VEGFR-1, VEGFR-2 and VEGFR-3), PDGFR, FGFR and c-Kit, etc. It can inhibit tumor progression by inhibiting angiogenesis and tumor growth at the same time.~TQB2450 injection is a humanized monoclonal antibody targeting programmed death ligand 1 (PD-L1) that prevents the binding of PD-L1 to the PD-1 and B7.1 receptors on the T-cell surface, allowing T-cell reactivation and thus enhancing the immune response.
Trial: NCT06475599
Drug: Chemotherapy drug
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Based on each patient's condition and previous treatment history, the investigator will select one of the chemotherapy drugs (including Paclitaxel, Albumin, Doxorubicin and Doxorubicin hydrochloride) for treatment.
Trial: NCT06235931
Drug: Darcilide +AI (letrozole/anastrozole/Exemestane) + pyrrotinib
RxNorm normalized name: Exemestane
DrugBank: Exemestane (DB00990)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darcilie: 125mg orally once a day, taken for 21 days and stopped for 7 days, 28 days as a cycle.~AI: Letrozole: 2.5mg orally once daily, or anastrozole 1mg orally once daily, or exemestane 25mg orally once daily.~Pyrrotinib: Initial dose of 240mg in the first week, if diarrhea and other side effects can be tolerated, 320 mg can be added in the second week, once a day, oral administration within 30 minutes after breakfast, 21 days for 1 cycle~All investigational drugs should be used for disease progression or when patients have an intolerable adverse reaction or are withdrawn from the study for other reasons.~Oral pyrrotinib is recommended along with prophylactic antidiarrheal medication. Antidiarrheal regimen 1: Oral imodium (2 tablets/times, 2 times a day) from the first week, 1 tablet, 2 times a day from the second week. Antidiarrheal regimen 2: montmorillonite powder (3 times a day, 1 pack/time)+ whole intestine sheng (3 pills/time 2 times a day).
Trial: NCT06280508
Drug: Adebrelimab, Apatinib, Gemcitabine, cisplatin
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chemotherapy combined with Adebrelimab and Apatinib neoadjuvant therapy for 3 cycles before surgery, and Adebrelimab combined with Apatinib adjuvant therapy for 6 months after surgery
Trial: NCT00253123
Drug: risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03998293
Drug: Somatostatin
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: infused to block endogenous insulin secretion over a 4 hour period
Trial: NCT06211335
Drug: Losartan
RxNorm normalized name: Losartan
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT06631365
Drug: Truvada
RxNorm normalized name: Truvada
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combination medication used in Human immunodeficiency virus (HIV) prevention, it blocks virus pathways to infection.
Trial: NCT05507463
Drug: KBP-7072
RxNorm normalized name: KBP-COVID-19
DrugBank: KBP-COVID-19 (DB15858)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KBP-7072
Trial: NCT04760301
Drug: local tranexamic acid injection
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: local tranexamic acid injection to cervix- 1 g tranexamic acid diluted in 10 ml saline
Trial: NCT04760301
Drug: IV 1 g tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV 1 g tranexamic acid diluted in 100 ml saline
Trial: NCT04870125
Drug: Inhaled Carbon Monoxide at CFK equation-determined personalized dose (200-500 ppm to achieve a COHb level of 6-8%)
RxNorm normalized name: carbon monoxide
DrugBank: Carbon monoxide (DB11588)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Carbon Monoxide at CFK equation-determined personalized dose (200-500 ppm to achieve a COHb level of 6-8%) for up to 90 minutes daily for 3 days.
Trial: NCT04700046
Drug: Mexiletine 167 mg
DrugBank: Mexiletine (DB00379)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mexiletine 167 mg (equivalent to mexiletine HCl 200 mg) immediate release, oral capsules.
Trial: NCT05303818
Drug: Rivaroxaban 10 MG
RxNorm normalized name: rivaroxaban 10 MG
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients in post-operative colonic cancer will receive rivaroxaban 10mg/daily for 28 days after surgery
Trial: NCT05977673
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tislelizumab 200mg IV day1
Trial: NCT06417489
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Henagliflozin Proline 10 mg qd+Regagliptin 100 mg qd+Metformin 500mg bid. The dose of metformin from the first to second week is 500mg bid, and the dose from the third to fourth week is 1000mg bid. If the maximum dose of metformin cannot be tolerated, the researcher shall increase the dosage according to the patient\&#39;s tolerance situation. The minimum dose is 1000mg/day.
Trial: NCT05114915
Drug: Albumin-bound docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Albumin-bound docetaxel by intravenous infusion
Trial: NCT04923139
Drug: Rivaroxaban (Xarelto, BAY59-7939)
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dosage at the discretion of the treating physician
Trial: NCT04450654
Drug: Gamunex-C
RxNorm normalized name: Gamunex-C
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gamunex-C IVIG will be given at week 0 and week 4
Trial: NCT04450654
Drug: Albumin
RxNorm normalized name: Albumin
DrugBank: Albumin human (DB00062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% albumin solution dosed at equivalent volume to the corresponding weight-based Gamunex-C IVIG dose will be given at week 0 and week 4
Trial: NCT06292650
Drug: ZM-02-H
RxNorm normalized name: ZM-39923
DrugBank: ZM-39923 (DB17064)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rAAV-PsCatCh2.0 intravitreal injection of high dose
Trial: NCT06353906
Drug: Carboplatin/Paclitaxel
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Induction: three cycles of intravenous carboplatin AUC5 (max 750 mg) and paclitaxel 175 mg/m2, during cycle 1, 2 and 3 (day 1, 22, 43)
Trial: NCT06353906
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Induction: two cycles of intravenous pembrolizumab 400 mg during cycle 1 and 3 (day 1 and 43)~Adjuvant: up to seven cycles of fixed-dose intravenous pembrolizumab 400 mg, on day 1 every 6 weeks within 3-9 weeks after surgery
Trial: NCT05662410
Drug: Three monthly injections of intravitreal aflibercept
RxNorm normalized name: aflibercept Injection
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Three monthly intravitreal injection of aflibercept (2.0mg / 0.05ml) after diagnosis of pathychoroid neovasculopathy.
Trial: NCT05091723
Drug: Nezulcitinib (TD-0903) Dose A
RxNorm normalized name: NEZULCITINIB
DrugBank: TD-0903 (DB16463)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TD-0903 Dose A
Trial: NCT05091723
Drug: Nezulcitinib (TD-0903) Dose B
RxNorm normalized name: TD-0903
DrugBank: TD-0903 (DB16463)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TD-0903 Dose B
Trial: NCT05334017
Drug: Xylometazoline 0,1%
DrugBank: Xylometazoline (DB06694)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 ml of 0,1% xylometazoline diluted with 1 ml of 0,9% isotonic saline solution given as a nasal spray
Trial: NCT02989012
Drug: Analogous Oseltamivir Phosphate Capsules
RxNorm normalized name: Oseltamivir Phosphate
DrugBank: Oseltamivir (DB00198)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 times a day,1 capsule each time.
Trial: NCT02989012
Drug: Oseltamivir Phosphate Capsules
RxNorm normalized name: Oseltamivir Phosphate Capsules
DrugBank: Oseltamivir (DB00198)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 times a day,1 capsule each time.
Trial: NCT05334017
Drug: Cocaine 4%
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml of 4% cocaine given as a nasal spray
Trial: NCT04381091
Drug: Idebenone 150 MG Oral Tablet
RxNorm normalized name: Idebenone 150 mg oral tablet
DrugBank: Idebenone (DB09081)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: idebenone 900 mg/day
Trial: NCT00000676
Drug: Clotrimazole
RxNorm normalized name: Clotrimazole
DrugBank: Clotrimazole (DB00257)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04736381
Drug: Belatacept Injection [Nulojix]
RxNorm normalized name: belatacept Injection [Nulojix]
DrugBank: Belatacept (DB06681)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Drugs administrated are part of the usual care
Trial: NCT04786795
Drug: Compound Azintamide Enteric-coated Tablets
RxNorm normalized name: Azintamide
DrugBank: Azintamide (DB13992)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the experimental group takes Compound Azintamide Enteric-coated Tablets.They were registered before medication and on days 14 and 28 after medication, and gastrointestinal symptoms were assessed at each follow-up visit
Trial: NCT00000676
Drug: Fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05794750
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Eligible subjects will receive short-course radiotherapy (SCRT), IMRT/VMAT, pelvic 25Gy/5f/1 week. Two weeks after the end of treatment, subjects continued to receive neoadjuvant chemotherapy combined with immunotherapy regimen for 4 cycles: AK104 10 mg/kg, intravenous infusion every 3 weeks (Q3W), plus CAPOX (capecitabine: 1000mg/m2, bid, po, d1-14, oxaliplatin: 130mg/m2, ivgtt, d1), Q3W. Neoadjuvant therapy was assessed 2 weeks after the end of neoadjuvant therapy, and TME surgery was performed 4 weeks after the end of neoadjuvant therapy (R0 surgery was performed).
Trial: NCT06124118
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Consolidation Durvalumab will be given per standard of care and institutional guidelines every 4 weeks for up to 12 cycles. Refer to package insert for detailed pharmacologic, dosing, and safety information.
Trial: NCT05906433
Drug: Kenalog with bupivacaine Injection
RxNorm normalized name: triamcinolone Injection [Kenalog]
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indications, relevant for this study include Kenalog injection for knee pain from osteoarthritis or inflammatory arthritis. A single injection to a patient who has no known allergies to anesthetic or corticosteroids would be administered during a scheduled clinical visit.
Trial: NCT04908605
Drug: Mirtazapine
RxNorm normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Every patient will be given mirtazapine 30 mg tablet
Trial: NCT06397807
Drug: Dinalbuphine sebacate
RxNorm normalized name: Dinalbuphine sebacate
DrugBank: Dinalbuphine sebacate (DB15341)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dinalbuphine sebacate (DS) is a long-acting injectable. With oil-based formulation, DS will slowly releases to blood vessel and be hydrolyzed to nalbuphine after intramuscularly injection. The analgesic effect lasts around 5 to 7 days.
Trial: NCT06397807
Drug: Analgesic injectables
RxNorm normalized name: ANALGESIC CREAM
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Opioids, NSAIDs or acetamol will be administrated as need.
Trial: NCT04910854
Drug: Surufatinib
RxNorm normalized name: Surufatinib
DrugBank: Surufatinib (DB15106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive oral Surufatinib at a dose of 300mg/d (once-daily dosing continuously, every 28-day treatment cycle), The curative effect was evaluated every 8 weeks.
Trial: NCT06341556
Drug: Zanubrutinib
RxNorm normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients diagnosed with mantle cell lymphoma who have achieved remission (CR or PR) by first-line immunochemotherapy, will be treated with Zanubrutinib monotherapy for 2 years (or until PD, intolerable toxicity, death, withdrawal, or study termination).
Trial: NCT05982496
Drug: FES
RxNorm normalized name: FESO
DrugBank: Fluoroestradiol F-18 (DB15690)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16-alpha-18F-fluoro-17-beta-estradiol(FES) is a radiolabeled form of estrogen binding to functionally active ER which will be used as radiotracer for the PET/MRI exam
Trial: NCT05869643
Drug: Low-dose STP0404 (Pirmitegravir)
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Once daily, oral capsule taken after breakfast
Trial: NCT05869643
Drug: Medium-dose STP0404 (Pirmitegravir)
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily, oral capsule taken after breakfast
Trial: NCT05781217
Drug: triptorelin, goserelin, leuprorelin
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ADT will consist of LHRH analogues (triptorelin, goserelin, leuprorelin) with bicalutamide 50 mg/day started 10 days before the first ADT injection to avoid LHRH-related flare-ups. Bicalutamide will be discontinued after 30 days. The LHRH analogue will be initiated prior to the start of radiotherapy and administered for 6 or 24 months depending on treatment allocation. The maximum time permitted between randomisation and administration of the first LHRH dose is 30 days. The maximum time from the first LHRH dose to the start of SRT is 60 days.
Trial: NCT06212388
Drug: Recombinant human interferon α1b
RxNorm normalized name: Interferon beta 1b (recombinant)
DrugBank: Interferon beta-1b (DB00068)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Recombinant human interferon α1b is a protein with potent antiviral, antiproliferative and immunomodulatory properties.